SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions

First-generation phosphodiesterase 4 (PDE4) inhibitors, such as rolipram, inhibit the activation of immune and inflammatory cells. The clinical use of these compounds is limited by gastrointestinal side effects, such as increased acid secretion and nausea. Consequently, the challenge has been to des...

Full description

Bibliographic Details

Published in:	The Journal of pharmacology and experimental therapeutics Vol. 284; no. 1; p. 420
Main Authors:	Barnette, M S, Christensen, S B, Essayan, D M, Grous, M, Prabhakar, U, Rush, J A, Kagey-Sobotka, A, Torphy, T J
Format:	Journal Article
Language:	English
Published:	United States 01-01-1998
Subjects:	Animals Anti-Inflammatory Agents - pharmacology Cyclohexanecarboxylic Acids - pharmacology Dose-Response Relationship, Drug Female Gastric Acid - secretion Humans In Vitro Techniques Male Nitriles Phosphodiesterase Inhibitors - pharmacology Pyrrolidinones - pharmacology Rabbits Rolipram
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!